Abstract
Depressive disorders are common sequelae of cancer and its treatment. Fortunately, most of them are transient and respond to information, adequate explanation and emotional support from those involved in patient care. This article concentrates on the less common but more severe depressive disorders which require pharmacological strategies in addition to psychosocial interventions. Guidelines are suggested for identifying depressive disorders and the importance of ruling out potentially reversible organic pathology which may be responsible for the mood disturbance is also emphasized. Estimates of the prevalence of depressive disorders among cancer patients are provided and practical advice is offered on the choice of antidepressant, dosage and side-effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
